Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A
SSSE:68826699.50
CNY
-3.06
(-2.98%)
ISIN
CNE100003RP1
Return %
Stock
S&P 500
1Y
-4.14
14.20
3Y
142.56
81.12
5Y
49.18
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Ze Lin Sheng
- Full Time Employees
- 1,055
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 262, Chenfeng Road Kunshan JS China 215300
- IPO Date
- Jan 23, 2020
- Website
- zelgen.com
- Similar Companies
- Business
- Suzhou Zelgen Biopharmaceuticals Co., Ltd. specializes in the research, development, manufacturing, and commercialization of innovative pharmaceuticals primarily targeting oncology, hematology, autoimmune diseases, and hepatobiliary conditions. Its core product portfolio includes small molecule targeted drugs such as donafenib toluene sulfonate tablets and gecacitinib hydrochloride tablets and creams; recombinant protein drugs including recombinant human thrombin for topical use, injectable recombinant human thyroid stimulating hormone, and various injectable biologics such as ZG005, ZG006, ZGGS18, and ZG0895; as well as advanced bispecific monoclonal antibodies and novel chemical entities designed to treat cancers like lung cancer, neuroendocrine carcinoma, hepatocellular carcinoma, and other solid tumors and hematological malignancies. The company also provides clinical trial drug manufacturing and processing services. Founded in 2009 and headquartered in Kunshan, Jiangsu Province, China, Zelgen operates research and development centers in both China and the United States and maintains commercial-scale manufacturing facilities for both small molecules and biologics. Recent strategic developments include obtaining orphan drug designation from the U.S. Food and Drug Administration for its injectable ZG006 targeting neuroendocrine carcinoma, and receiving clinical trial approvals for combination therapies involving ZG006 with immune checkpoint inhibitors and chemotherapy agents for advanced cancers. In 2024, Zelgen completed full equity acquisition of its U.S. subsidiary Gensun and plans to dissolve it while pursuing a listing of H shares on the Hong Kong Stock Exchange to expand its capital market presence. The company is actively engaged in capital increases alongside strategic investors in related biotech and semiconductor ventures, reflecting a broader business diversification strategy. Its financial performance in 2025 shows robust revenue growth exceeding 50% year over year, driven by commercial scale production and multiple advanced clinical-stage product pipelines. Suzhou Zelgen Biopharmaceuticals targets both the rapidly growing Chinese pharmaceutical market and international markets, leveraging proprietary technology platforms for precision small molecule drug development and complex recombinant protein therapeutics. Its product pipeline is supported by integrated capabilities from drug discovery through manufacturing and commercialization, with significant focus on innovation for unmet medical needs in oncology, bleeding disorders, liver and gallbladder diseases, and immune-inflammatory conditions. The company's recent operational and strategic shifts position it as a competitive innovative pharmaceutical enterprise listed on the Shanghai STAR Market (Ticker 688266.SS) and preparing for cross-border capital market expansion through a Hong Kong listing, indicating its ambition to become a leading biopharmaceutical player domestically and globally. Suzhou Zelgen Biopharmaceuticals remains committed to developing safe, effective, and accessible therapies with independent intellectual property rights to meet the needs of patients worldwide. Its product range, strategic investments, and capital moves reflect ongoing efforts to bolster innovation, scale production, and enhance market penetration in key therapeutic segments.